Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer

Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies1. After surgery, estrogen receptor (ERα) positive breast cancer (BCa) patients are treated with adjuvant endocrine therapy2 including selective estrogen receptor modulators (SERMs) an...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nat Genet
Hlavní autoři: Magnani, Luca, Frige, Gianmaria, Gadaleta, Raffaella Maria, Corleone, Giacomo, Fabris, Sonia, Kempe, Mannus H., Vershure, Pernette J., Barozzi, Iros, Vircillo, Valentina, Hong, Sung-Pil, Perone, Ylenia, Saini, Massimo, Trumpp, Andreas, Viale, Giuseppe, Neri, Antonino, Ali, Simak, Colleoni, Marco Angelo, Pruneri, Giancarlo, Minucci, Saverio
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5326683/
https://ncbi.nlm.nih.gov/pubmed/28112739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ng.3773
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky